相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
Andrea Wang-Gillam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Yongwoo David Seo et al.
CLINICAL CANCER RESEARCH (2019)
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Jorge Blando et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
Jodi A. McKenzie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.
Pankaj Gaur et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses
Rafael Cubas et al.
JOURNAL OF IMMUNOLOGY (2018)
CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways
Shiri Klein et al.
CANCER RESEARCH (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells
Y. Deng et al.
ONCOGENE (2017)
Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
Michal Abraham et al.
CLINICAL CANCER RESEARCH (2017)
Evaluation of assay interference and interpretation of CXCR4 receptor occupancy results in a preclinical study with MEDI3185, a fully human antibody to CXCR4
Martin Schwickart et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Amnon Peled et al.
CLINICAL CANCER RESEARCH (2014)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Michael J. Gerdes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer
Duha Fahham et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation
M. Abraham et al.
LEUKEMIA (2009)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-Benzoyl-TNI4003
Michal Abraham et al.
STEM CELLS (2007)
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer
H Tamamura et al.
FEBS LETTERS (2003)
Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives
H Tamamura et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2003)
分享论文
